Expanded Access
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing novel proprietary therapeutics for breast cancer, breast conditions, and other rare diseases.
Atossa Therapeutics’ development resources are focused on conducting clinical studies to fully answer important scientific questions about the potential risks and benefits of the investigational products, and to obtain marketing approval by the FDA and other regulatory health authorities.
Atossa Therapeutics is committed to making investigational products available to seriously ill patients who have exhausted other treatment options. A treating physician, who is able to comply with the requirements that are stated in this document, may request information about how to apply for access to Atossa Therapeutics’ investigational products by contacting the Company.
The purpose of this policy is to describe the requirements for Expanded Access to Atossa Therapeutics investigational products to patients outside of a clinical study. To read our full expanded access policy CLICK HERE.